10
Participants
Start Date
March 31, 2012
Primary Completion Date
May 31, 2013
Study Completion Date
December 31, 2013
Exenatide
The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
Children's Hospital of Los Angeles, Los Angeles
Children's Hospital Los Angeles
OTHER